We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Final Guidance Calls for Greater Numbers of Geriatric Patients in Late-Stage Trials
Final Guidance Calls for Greater Numbers of Geriatric Patients in Late-Stage Trials
March 14, 2012
Drugmakers should consider including more than 100 geriatric patients in Phase II and III databases for new drugs to account for the increasing prevalence and complexity of the elderly patient population, according to a final International Conference on Harmonisation (ICH) guidance adopted by the FDA.